Seikagaku Corporation

Seikagaku Corporation, a pharmaceutical preparation manufacturer headquartered in Japan, reported total global emissions of approximately 89.1 billion kg CO2e in 2025. This figure encompasses Scope 1, 2, and 3 emissions. For the same year, Scope 1 emissions were around 8.45 million kg CO2e, Scope 2 emissions were approximately 21,000 kg CO2e, and Scope 3 emissions totalled about 75.7 billion kg CO2e.

In 2024, Seikagaku Corporation's total global emissions were approximately 93.6 billion kg CO2e. This included Scope 1 emissions of roughly 8.35 million kg CO2e, Scope 2 emissions of approximately 13.0 million kg CO2e, and Scope 3 emissions totalling about 72.3 billion kg CO2e.

The company's emissions for 2023 were approximately 84.3 billion kg CO2e in total. This breakdown included Scope 1 at approximately 8.29 million kg CO2e, Scope 2 at approximately 14.4 million kg CO2e, and Scope 3 at about 61.0 billion kg CO2e.

Seikagaku Corporation's reported Scope 1 and 2 emissions for 2022 were approximately 23.4 million kg CO2e. For 2021, the combined Scope 1 and 2 emissions were approximately 23.8 million kg CO2e. In 2020, the company reported Scope 1 and 2 emissions of about 24.7 million kg CO2e, and in 2019, this figure was approximately 25.5 million kg CO2e.

While specific reduction targets are not detailed, Seikagaku Corporation's reporting consistently includes Scope 1, 2, and 3 emissions, with an ongoing effort to disclose and monitor these across its global operations in the pharmaceutical preparation manufacturing sector. Notably, "scope_3/purchased_goods_and_services" is listed as a missing data point in their recent reports.